Liminatus Pharma Stock (NASDAQ:LIMN)

Ownership Financials Chart

Previous Close

$3.88

52W Range

$3.29 - $141.50

50D Avg

$4.52

200D Avg

$13.73

Market Cap

$4.96M

Avg Vol (3M)

$453.28K

Beta

0.74

Div Yield

-

LIMN Company Profile

Liminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical development phase, dedicated to pioneering new treatments for cancer. The company's headquarters are located in La Palma, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

1

IPO Date

May 01, 2025

Website

LIMN Performance

LIMN Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	-
Operating Income	$-2.97M	$-2.91M	$-2.59M
Net Income	$-10.21M	$-2.90M	$-1.23M
EBITDA	$-2.97M	$-2.75M	$-1.09M
Basic EPS	$-0.43	$-0.40	$-0.15
Diluted EPS	$-0.43	$-0.40	$-0.15

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

Ticker	Company
DYAI	Dyadic International, Inc.
BTAI	BioXcel Therapeutics, Inc.
JSPR	Jasper Therapeutics, Inc.
SABS	SAB Biotherapeutics, Inc.
ATHE	Alterity Therapeutics Limited
EVAX	Evaxion Biotech A/S
MURA	Mural Oncology plc
GBIO	Generation Bio Co.